Saskia C. Langemeijer

Nijmegen, GE, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

The Predictive Value of Serum Erythropoietin Levels Measured at Diagnosis in Patients With Myelodysplastic Syndromes.

The Predictive Value of Serum Erythropoietin Levels Measured at Diagnosis in Patients With Myelodysplastic Syndromes.

Journal: EJHaem

Published: January 29, 2026

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency.

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency.

Journal: British journal of clinical pharmacology

Published: December 22, 2025

Anti-thymocyte globulin-based treatment frequently leads to enduring treatment success in both old and young adult patients with aplastic anaemia: a real-world analysis from the Dutch aplastic anaemia registry.

Anti-thymocyte globulin-based treatment frequently leads to enduring treatment success in both old and young adult patients with aplastic anaemia: a real-world analysis from the Dutch aplastic anaemia registry.

Journal: Annals of hematology

Published: December 05, 2025

Tailoring Eculizumab Treatment: Evaluation of Model-Informed Precision Dosing for Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome.

Tailoring Eculizumab Treatment: Evaluation of Model-Informed Precision Dosing for Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome.

Journal: Therapeutic drug monitoring

Published: October 01, 2025

Laboratory findings in patients treated with complement factor C3 inhibitor pegcetacoplan.

Laboratory findings in patients treated with complement factor C3 inhibitor pegcetacoplan.

Journal: Clinical chemistry and laboratory medicine

Published: September 26, 2025

Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.

Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.

Journal: British journal of haematology

Published: September 03, 2025

Model-Informed Precision Dosing of Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Model-Informed Precision Dosing of Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Journal: Clinical pharmacokinetics

Published: May 22, 2025

Common Clonal Origin of Core-Binding-Factor AML in Both Donor and Recipient Following Kidney Transplantation.

Common Clonal Origin of Core-Binding-Factor AML in Both Donor and Recipient Following Kidney Transplantation.

Journal: Case reports in hematology

Published: May 19, 2025

What are the most important quality of life domains for patients with aplastic anemia and paroxysmal nocturnal hemoglobinuria?

What are the most important quality of life domains for patients with aplastic anemia and paroxysmal nocturnal hemoglobinuria?

Journal: Annals of hematology

Published: February 24, 2025

Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.

Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.

Journal: The Lancet. Haematology

Published: January 13, 2025

Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry.

Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry.

Journal: Haematologica

Published: October 31, 2024

Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower-risk myelodysplastic syndromes.

Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower-risk myelodysplastic syndromes.

Journal: HemaSphere

Published: August 30, 2024

Showing 1-12 of 56

Last Updated: 09/26/2026